Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression

NCT05041842 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05041842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05041842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 17, 2021
Completion date
April 30, 2026
Enrollment
53 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer with a isolated brain progression